Aileron Therapeutics (Aileron Therapeutics) Cost of Goods Sold : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Aileron Therapeutics Cost of Goods Sold?

Aileron Therapeutics's cost of goods sold for the three months ended in Dec. 2023 was $0.00 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Aileron Therapeutics's Gross Margin % for the three months ended in Dec. 2023 was %.

Cost of Goods Sold is also directly linked to Inventory Turnover.

Aileron Therapeutics Cost of Goods Sold Historical Data

The historical data trend for Aileron Therapeutics's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aileron Therapeutics Cost of Goods Sold Chart

Aileron Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cost of Goods Sold

Get a 7-Day Free Trial

Aileron Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cost of Goods Sold	Get a 7-Day Free Trial															-	-	-	-	-

Aileron Therapeutics Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Aileron Therapeutics (NAS:ALRN) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Aileron Therapeutics's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	(Revenue	-	Cost of Goods Sold)	/	Revenue
	=	(0	-	0)	/	0
	=	%

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Aileron Therapeutics's Inventory Turnover for the three months ended in Dec. 2023 is calculated as:

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.

Aileron Therapeutics Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Aileron Therapeutics's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.

Aileron Therapeutics (Aileron Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aileron Therapeutics Inc (NAS:ALRN) » Definitions » Cost of Goods Sold

Comparable Companies

Traded in Other Exchanges

N/A

Address

285 Summer Street, Unit 101, Boston, MA, USA, 02210

Website

https://www.aileronrx.com

Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects.

Executives

James Brian Windsor	officer: See Remarks	2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
William Fairey	director	C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043
Alan A Musso	director	FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Susan L. Drexler	officer: See Remarks	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Muneer A Satter	10 percent owner	C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Reinhard J. Ambros	director	C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Von Rickenbach Josef H	director	C/O PAREXEL INTERNATIONAL CORPORATION, WALTHAM MA 02451-1163
Jeffrey Allen Bailey	director	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Vojo Vukovic	officer: SVP, Chief Medical Officer	C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421
Kathryn Gregory	officer: SVP, Chief Business Officer	305 THAYER POND ROAD, WILTON CT 06897
William Mckee	director
Nolan Howard Sigal	director	941 BERRY AVENUE, LOS ALTOS CA 94024
Novartis Bioventures Ltd	10 percent owner	C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
Rick Wanstall	officer: VP, Finance and Operations	C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472
Longenecker John P Phd	officer: President and CEO	10445 PACIFIC CENTER CT, SAN DIEGO CA 92121